0000950170-25-093445.txt : 20250702 0000950170-25-093445.hdr.sgml : 20250702 20250702200009 ACCESSION NUMBER: 0000950170-25-093445 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250221 FILED AS OF DATE: 20250702 DATE AS OF CHANGE: 20250702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cabell Christopher CENTRAL INDEX KEY: 0001814928 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 251103428 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 263407249 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 N. WEST STREET, SUITE 1200 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: (302) 295-3800 MAIL ADDRESS: STREET 1: 1000 N. WEST STREET, SUITE 1200 CITY: WILMINGTON STATE: DE ZIP: 19801 4/A 1 ownership.xml 4/A X0508 4/A 2025-02-21 2025-02-25 false 0001750149 Inhibikase Therapeutics, Inc. IKT 0001814928 Cabell Christopher 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 false true false false President & Head of R&D false Stock Option (Right to Buy) 2.97 2025-02-21 4 A false 1100705 0 A 2035-02-21 Common Stock 1100705 1100705 D The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price. The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date. /s/ Mark Iwicki, attorney-in-fact 2025-07-02